Head and Neck Cancer

Multimodality Management
1. Auflage 2016
ISBN: 978-3-319-27599-4
Verlag: Springer International Publishing

Buch, Englisch, 878 Seiten, HC runder Rücken kaschiert, Format (B × H): 215 mm x 285 mm, Gewicht: 26097 g

This second edition provides a comprehensive view of consolidated and innovative concepts, in terms of both diagnosis and treatment. Written by leading international physicians and investigators, this book emphasizes the necessity of combining local and systemic treatments to achieve the objective of yielding higher cure rates and lower toxicities. Heavily updated from the previous edition, it highlights new surgery and radiotherapy techniques, disease awareness, patient quality of life, and comprehensive management. 
Head-and-neck cancers are a complex clinical entity and their response to treatment is also known to vary markedly in function of host-related factors. Notwithstanding the impressive progresses observed in the field of imaging, head and neck cancers are often diagnosed at a late stage and the presence of locally advanced disease in a significant number of patients implies the use of aggressive treatments in order to both ensure local disease control and reduce distant metastasis risks. 
In comparison with the first edition, Head and Neck Cancer, Second Edition provides a detailed update of innovative concepts in chemo- and bio-radiation, viral infection impact on tumor growth and response to treatment, and impact of tumor- and host-related factors on treatment outcome. 

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Bernier, Jacques

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Chirurgie Kopf- & Halschirurgie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

Ch. 1: Epidemiology and Aetiology of Head and Neck Cancers.- Ch. 2: Head and Neck Cancer Prevention.- Ch. 3: Cellular and Molecular Pathology of Head and Neck Tumors.- Ch. 4: Oncogenomics/Proteomics of Head and Neck Cancers.- Ch. 5: Genetics and Epigenetics of Head and Neck Cancer.- Ch. 6: Immunology of Head and Neck Cancer.- Ch. 7: Biomarkers in Head and Neck Cancer.- Ch. 8: HPV and EBV in Head and Neck Cancer.- Ch. 9: Head and Neck Cancer Staging and Prognosis: Perspectives of the UICC and the AJCC.- Ch. 10: Preclinical Models of Head and Neck Squamous Cell Carcinoma.- Ch. 11: Translational Research in Head and Neck Oncology.- Ch. 12: Hypoxia in Head and Neck Cancers: Clinical Relevance and Treatment.- Ch. 13: Imaging of Head and Neck Cancers.- Ch. 14: Ultrasound Investigations in Head & Neck Cancer Patients.- Ch. 15: Sentinel Node Biopsy.- Ch. 16: Intensity-Modulated Radiation Therapy for Head and Neck Cancer.- Ch. 17: Stereotactic Radiotherapy in Head and Neck Cancer Patients.- Ch. 18: Proton Beam Therapy for Head and Neck Cancer.- Ch. 19: Principles of Systemic Chemotherapy for Squamous Cell Head and Neck Cancer.- Ch. 20: Molecular Targeted Therapies in Head and Neck Cancer.- Ch. 21: Laser Endoscopic Treatment.- Ch. 22: Transoral robotic surgery in head and neck cancer.- Ch. 23: Multidisciplinary Management of Skull Base and Superstructure Tumors.- Ch. 24: Multidisciplinary management of oral cavity and maxillary sinus cancers.- Ch. 25: Oral Oncology.- Ch. 26: Management of Nasopharyngeal Carcinoma.- Ch. 27: Multidisciplinary management of oropharynx carcinomas.- Ch. 28: Multidisciplinary Management of Hypopharyngeal Carcinoma.- Ch. 29: Cancers of the Larynx: Tis, T1, T2 Evaluation and Management.- Ch. 30: Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers.- Ch. 31: Programs of Organ and Function Preservation.- Ch. 32: Principles and New Approaches in Surgical Reconstruction.- Ch. 33: Multidisciplinary treatment of the neck.- Ch. 34: Postoperative Management of High-Risk Resectable Head and Neck Cancer.- Ch. 35: Multidisciplinary Approach of Unresectable Head and Neck Cancer.- Ch. 36: Management of Salivary Gland Cancer.- Ch. 37: Primary Mucosal Melanomas of the Head and Neck.- Ch. 38: Head & Neck Cutaneous Melanoma.- Ch. 39: Cervical Lymph Node Metastases Of Squamous Cell Carcinoma From An Unknown Primary Site.- Ch. 40: The Management of Thyroid and Parathyroid Cancer.- Ch. 41: Head and Neck Paragangliomas.- Ch. 42: Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.- Ch. 43: Phase I study methodology in head and neck oncology.- Ch. 44: Treatment of the Elderly Head and Neck Cancer Patient.- Ch. 45: Normal Tissue Complications and Protection in Head and Neck Cancer Patients.- Ch. 46: Advances in Management of Complications for Head and Neck Cancer Therapy.- Ch. 47: Rehabilitation of Heavily Treated Head and Neck Cancer Patients.- Ch. 48: Salvage Therapy in Head and Neck Cancer Patients.- Ch. 49: Quality of Life in Head and Neck Cancer Patients.- Ch. 50: Psycho-oncologic aspects of head and neck cancer patients.- Ch. 51: Advances in Nanomedicine for Head and Neck Cancer.- Ch. 52: Head and Neck Quality Assurance 2014.

Über Autor(innen)

After obtaining his degree in Radio-Oncology at the University of Liege, Belgium, Jacques Bernier completed his training at the MD Anderson Cancer Center, Houston, and the Curie Institute, Paris. In 2006 he joined the Swiss Genolier Medical Network, where since then he has been chairing the Radio-Oncology Department. Throughout most of his career, Jacques Bernier has been heavily involved with translational and clinical research. From 2000 to 2006 Jacques Bernier was Chairman of the Head and Neck Group of the EORTC. He currently serves as an Editorial Board member of various international peer-reviewed journals, including “Journal of Clinical Oncology”. He is an Associate Editor of “Annals of Oncology” (since 2010), and “Oral Oncology” (since January 2011). A Course Director at the European School of Oncology since 1990, Jacques Bernier is also the Chairman of the International Conference on Translational Research in Radio-Oncology - ICTR, organized every three years in Switzerland.He serves as a regular member of advisory boards for many pharmaceutical companies. He is President of the Foundation for the Advancement of Radiation Oncology – FARO, in Geneva, member of the Executive Board of Euro-Asian Society of Mastology - EURAMA, Board of Trustees of “Science for Peace” and Scientific Committee of the “Umberto Veronesi Foundation” in Milan.